Natco Pharma Ltd
Natco Pharma Ltd Share Price Today: Live Updates & Key Insights
Get insights on Natco Pharma Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Natco Pharma Ltd Share Price Chart
Natco Pharma Ltd Fundamentals
Traded Volume: 7,31,845
Market Cap(Cr): 15,489
Avg Traded Price 864.53
1 Year return -37.09%
Upper Circuit 872.9
Lower Circuit 857
P/E TTM 10.00
P/B Ratio 86.00
Traded Value(Cr) 6329.00
EPS TTM 85.908
Book value 85.908
Dividend 1.00%
Natco Pharma Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Natco Pharma Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Natco Pharma Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W +4.68%
1M +3.74%
3M -2.71%
1Y -37.09%
YTD -37.79%
Natco Pharma Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Natco Pharma Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 77.51L
Day Before Yesterday 23.14L
1W Avg 23.69L
1M Avg 8.61L
3M Avg 6.33L
Natco Pharma Ltd Technical Details
Natco Pharma Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 null
Support 2 null
Support 3 null
Pivot Point : null
Resistance 1 null
Resistance 2 null
Resistance 3 null
Natco Pharma Ltd Corporate Actions
Natco Pharma Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Natco Pharma Ltd’s capital allocation strategies.
All
Ex-Date 20-Nov-2025 Type D Description 1.50/share@75.00% Record Date 20-Nov-2025 Ratio 75.00
Ex-Date 19-Aug-2025 Type D Description 2.00/share@100.00% Record Date 19-Aug-2025 Ratio 100.00
Ex-Date 18-Feb-2025 Type D Description 1.50/share@75.00% Record Date 18-Feb-2025 Ratio 75.00
Ex-Date 27-Nov-2024 Type D Description 1.50/share@75.00% Record Date 27-Nov-2024 Ratio 75.00
Ex-Date 23-Aug-2024 Type D Description 3.00/share@150.00% Record Date 23-Aug-2024 Ratio 150.00
Ex-Date 26-Feb-2024 Type D Description 1.25/share@62.50% Record Date 26-Feb-2024 Ratio 62.50
Ex-Date 24-Nov-2023 Type D Description 1.25/share@62.50% Record Date 24-Nov-2023 Ratio 62.50
Ex-Date 22-Aug-2023 Type D Description 7.00/share@350.00% Record Date 22-Aug-2023 Ratio 350.00
Ex-Date 21-Feb-2023 Type D Description 1.25/share@62.50% Record Date 21-Feb-2023 Ratio 62.50
Ex-Date 21-Nov-2022 Type D Description 0.75/share@37.50% Record Date 22-Nov-2022 Ratio 37.50
Ex-Date 19-Aug-2022 Type D Description 3.50/share@175.00% Record Date 22-Aug-2022 Ratio 175.00
Ex-Date 24-Feb-2022 Type D Description 2.00/share@100.00% Record Date 25-Feb-2022 Ratio 100.00
Ex-Date 23-Nov-2021 Type D Description 0.50/share@25.00% Record Date 24-Nov-2021 Ratio 25.00
Ex-Date 24-Aug-2021 Type D Description 2.00/share@100.00% Record Date 25-Aug-2021 Ratio 100.00
Ex-Date 22-Feb-2021 Type D Description 1.00/share@50.00% Record Date 23-Feb-2021 Ratio 50.00
Ex-Date 24-Nov-2020 Type D Description 3.00/share@150.00% Record Date 25-Nov-2020 Ratio 150.00
Ex-Date 21-Aug-2020 Type D Description 1.25/share@62.50% Record Date 24-Aug-2020 Ratio 62.50
Ex-Date 26-Jun-2020 Type D Description 1.00/share@50.00% Record Date 29-Jun-2020 Ratio 50.00
Ex-Date 24-Feb-2020 Type D Description 3.50/share@175.00% Record Date 25-Feb-2020 Ratio 175.00
Ex-Date 21-Nov-2019 Type D Description 1.00/share@50.00% Record Date 22-Nov-2019 Ratio 50.00
Ex-Date 22-Aug-2019 Type D Description 1.25/share@62.50% Record Date 23-Aug-2019 Ratio 62.50
Ex-Date 06-Jun-2019 Type D Description 1.25/share@62.50% Record Date 07-Jun-2019 Ratio 62.50
Ex-Date 21-Feb-2019 Type D Description 3.50/share@175.00% Record Date 22-Feb-2019 Ratio 175.00
Ex-Date 20-Aug-2018 Type D Description 1.50/share@75.00% Record Date 21-Aug-2018 Ratio 75.00
Ex-Date 15-Feb-2018 Type D Description 7.00/share@350.00% Record Date 17-Feb-2018 Ratio 350.00
Ex-Date 16-Aug-2017 Type D Description 1.25/share@62.50% Record Date 18-Aug-2017 Ratio 62.50
Ex-Date 23-Feb-2017 Type D Description 6.00/share@300.00% Record Date 27-Feb-2017 Ratio 300.00
Ex-Date 19-Aug-2016 Type D Description 0.75/share@37.50% Record Date 22-Aug-2016 Ratio 37.50
Ex-Date 22-Feb-2016 Type D Description 1.25/share@62.50% Record Date 23-Feb-2016 Ratio 62.50
Ex-Date 26-Nov-2015 Type S Description share@1:5.00 Record Date 28-Nov-2015 Ratio 1:5.00
Ex-Date 24-Feb-2015 Type D Description 5.00/share@50.00% Record Date 25-Feb-2015 Ratio 50.00
Ex-Date 24-Feb-2014 Type D Description 5.00/share@50.00% Record Date 25-Feb-2014 Ratio 50.00
Ex-Date 22-Feb-2013 Type D Description 4.00/share@40.00% Record Date 25-Feb-2013 Ratio 40.00
Ex-Date 22-Feb-2012 Type D Description 3.00/share@30.00% Record Date 23-Feb-2012 Ratio 30.00
Ex-Date 24-Feb-2011 Type D Description 2.00/share@20.00% Record Date 25-Feb-2011 Ratio 20.00
Ex-Date 05-Feb-2010 Type D Description 2.00/share@20.00% Record Date 08-Feb-2010 Ratio 20.00
Ex-Date 04-Jun-2009 Type D Description 1.25/share@12.50% Record Date 05-Jun-2009 Ratio 12.50
Ex-Date 12-Nov-2007 Type D Description 1.25/share@12.50% Record Date 13-Nov-2007 Ratio 12.50
Dividends
Announcement Date 20-Nov-2025 Ex Dividend Date 20-Nov-2025 Dividend(%) 75
Announcement Date 19-Aug-2025 Ex Dividend Date 19-Aug-2025 Dividend(%) 100
Announcement Date 18-Feb-2025 Ex Dividend Date 18-Feb-2025 Dividend(%) 75
Announcement Date 27-Nov-2024 Ex Dividend Date 27-Nov-2024 Dividend(%) 75
Announcement Date 23-Aug-2024 Ex Dividend Date 23-Aug-2024 Dividend(%) 150
Announcement Date 26-Feb-2024 Ex Dividend Date 26-Feb-2024 Dividend(%) 63
Announcement Date 24-Nov-2023 Ex Dividend Date 24-Nov-2023 Dividend(%) 63
Announcement Date 22-Aug-2023 Ex Dividend Date 22-Aug-2023 Dividend(%) 350
Announcement Date 21-Feb-2023 Ex Dividend Date 21-Feb-2023 Dividend(%) 63
Announcement Date 21-Nov-2022 Ex Dividend Date 21-Nov-2022 Dividend(%) 38
Announcement Date 19-Aug-2022 Ex Dividend Date 19-Aug-2022 Dividend(%) 175
Announcement Date 24-Feb-2022 Ex Dividend Date 24-Feb-2022 Dividend(%) 100
Announcement Date 23-Nov-2021 Ex Dividend Date 23-Nov-2021 Dividend(%) 25
Announcement Date 24-Aug-2021 Ex Dividend Date 24-Aug-2021 Dividend(%) 100
Announcement Date 22-Feb-2021 Ex Dividend Date 22-Feb-2021 Dividend(%) 50
Announcement Date 24-Nov-2020 Ex Dividend Date 24-Nov-2020 Dividend(%) 150
Announcement Date 21-Aug-2020 Ex Dividend Date 21-Aug-2020 Dividend(%) 63
Announcement Date 26-Jun-2020 Ex Dividend Date 26-Jun-2020 Dividend(%) 50
Announcement Date 24-Feb-2020 Ex Dividend Date 24-Feb-2020 Dividend(%) 175
Announcement Date 21-Nov-2019 Ex Dividend Date 21-Nov-2019 Dividend(%) 50
Announcement Date 22-Aug-2019 Ex Dividend Date 22-Aug-2019 Dividend(%) 63
Announcement Date 06-Jun-2019 Ex Dividend Date 06-Jun-2019 Dividend(%) 63
Announcement Date 21-Feb-2019 Ex Dividend Date 21-Feb-2019 Dividend(%) 175
Announcement Date 20-Aug-2018 Ex Dividend Date 20-Aug-2018 Dividend(%) 75
Announcement Date 15-Feb-2018 Ex Dividend Date 15-Feb-2018 Dividend(%) 350
Announcement Date 16-Aug-2017 Ex Dividend Date 16-Aug-2017 Dividend(%) 63
Announcement Date 23-Feb-2017 Ex Dividend Date 23-Feb-2017 Dividend(%) 300
Announcement Date 19-Aug-2016 Ex Dividend Date 19-Aug-2016 Dividend(%) 38
Announcement Date 22-Feb-2016 Ex Dividend Date 22-Feb-2016 Dividend(%) 63
Announcement Date 24-Feb-2015 Ex Dividend Date 24-Feb-2015 Dividend(%) 50
Announcement Date 24-Feb-2014 Ex Dividend Date 24-Feb-2014 Dividend(%) 50
Announcement Date 22-Feb-2013 Ex Dividend Date 22-Feb-2013 Dividend(%) 40
Announcement Date 22-Feb-2012 Ex Dividend Date 22-Feb-2012 Dividend(%) 30
Announcement Date 24-Feb-2011 Ex Dividend Date 24-Feb-2011 Dividend(%) 20
Announcement Date 05-Feb-2010 Ex Dividend Date 05-Feb-2010 Dividend(%) 20
Announcement Date 04-Jun-2009 Ex Dividend Date 04-Jun-2009 Dividend(%) 13
Announcement Date 12-Nov-2007 Ex Dividend Date 12-Nov-2007 Dividend(%) 13
Bonus
No Bonus has been declared by NATCOPHARM
Splits
Record Date 28-Nov-2015 Split Date 26-Nov-2015 Face Value (Before/After) 10.00/2.00
Others
Rights No Rights has been declared by NATCOPHARM
Natco Pharma Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Natco Pharma Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Natco Pharma Ltd's relative performance and valuation against major competitors.
Stock Name Sai Life Sciences Ltd ₹861.35 (-1.44%) M. Cap (Cr) 181.03 1 Yr Return (%) NaN% P/E (TTM) 63.21 PB Ratio 18.71
Stock Name Alembic Pharmaceuticals Ltd ₹901.00 (+0.17%) M. Cap (Cr) 177.10 1 Yr Return (%) -13.19% P/E (TTM) 27.92 PB Ratio 3.41
Stock Name Jubilant Pharmova Ltd ₹1057.80 (-2.06%) M. Cap (Cr) 168.51 1 Yr Return (%) -6.42% P/E (TTM) 35.27 PB Ratio 2.84
Stock Name Natco Pharma Ltd ₹864.80 (-0.52%) M. Cap (Cr) 154.89 1 Yr Return (%) -37.09% P/E (TTM) 10.07 PB Ratio 2.04
Stock Name Caplin Point Laboratories Ltd ₹1918.80 (-0.09%) M. Cap (Cr) 145.85 1 Yr Return (%) -1.24% P/E (TTM) 24.77 PB Ratio 5.74
Stock Name Acutaas Chemicals Ltd ₹1701.80 (-1.77%) M. Cap (Cr) 139.33 1 Yr Return (%) +62.23% P/E (TTM) 62.21 PB Ratio 11.59
Stock Name Granules India Ltd ₹544.20 (-1.20%) M. Cap (Cr) 132.06 1 Yr Return (%) -0.12% P/E (TTM) 25.75 PB Ratio 3.55
Natco Pharma Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Natco Pharma Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 1662.00 Mar 2024 1196.40 Mar 2023 784.40 Mar 2022 57.70 Mar 2021 183.50
PARTICULARS Investing Activities Mar 2025 -1443.90 Mar 2024 -960.50 Mar 2023 -436.60 Mar 2022 -92.50 Mar 2021 -3.20
PARTICULARS Financing Activities Mar 2025 -212.40 Mar 2024 -237.30 Mar 2023 -346.80 Mar 2022 35.60 Mar 2021 -183.10
PARTICULARS Net Cash Flow Mar 2025 5.70 Mar 2024 -1.40 Mar 2023 1.00 Mar 2022 0.80 Mar 2021 -2.80
Natco Pharma Ltd Shareholding Pattern
This shows the ownership breakdown of Natco Pharma Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 49.48%
Public 30.56%
Other Institutions 3.67%
FII 14.09%
Mutual Funds 2.2%
About Natco Pharma Ltd
Natco Pharma Limited was originally incorporated on 19 September 1981 as private limited company as 'Natco Fine Pharmaceuticals Private Limited'. The name of the company was changed to Natco Pharma Limited and a fresh certificate of incorporation dated 30 December 1994 issued by the RoC, Andhra Pradesh. Natco Pharma is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs). The Company's focus is primarily on niche therapeutic areas and complex products. It sells products in over 40 countries. FDF products are sold in the United States, India, Europe and the rest of the world (RoW). Natco's API products are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, Natco has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.In 1988, the company inaugurated a Parenterals manufacturing facility at Nagarajuna Sagar, Telangana. In 1993, the company inaugurated its chemical division at Mekaguda, Telangana. On 1 April 1995, Natco Parenterals Limited, Natco Laboratories Limited and Dr. Karanth Pharma Labs Private Limited merged with Natco Pharma. In 1997, Natco Pharma inaugurated Natco Research Center (NRC) at Sanathnagar, Hyderabad. In 2003, Natco Pharma launched its Oncology division with introduction of flagship brand VEENAT (generic Imatinib Mesylate) for the treatment of chronic myelogenous leukemia. In 2006, Natco Pharma inaugurated a world class finished dosage facility at Dehradun, Uttarakhand. In 2007, Natco Pharma launched its first abbreviated new drug application (ANDA) in the US market. During the year, the company acquired Savemart Pharmacy in USA.In 2008, Natco Pharma filed its first Paragraph IV filing in the US market. In 2009, Natco Pharma's turnover reached $100 million milestone. In 2011, Natco Pharma and Levomed LLC, USA formed a joint venture company, Natcofarma Do Brasil for sales and distribution in Brazil. In 2012, Natco Pharma won the first ever compulsory license from Bayer for its patent-protected anti-cancer drug Nexavar in India. During the year, the company established Natco Pharma Asia Pte Ltd as a wholly owned subsidiary for sales and distribution in Singapore. In 2013, Natco Pharma established a subsidiary Natco Pharma Canada for sales and distribution in Canada. In 2014, Natco Pharma established a subsidiary Natco Pharma Australia Pty Ltd for sales and distribution in Australia. On 9 March 2015, Natco Pharma announced that it has launched the first generic version of sofosbuvir in Nepal. Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc., under its brand Sovaldi. On 11 March 2015, Natco Pharma announced that it is the first company in India to get approval for generic sofosbuvir tablets, 400mg, from Drugs Controller General (India). Natco will market generic sofosbuvir under its brand HEPCINAT and through strategic partners in India.The Board of Directors of Natco Pharma at its meeting held on 30 March 2016 approved the sale of its Save Mart Pharmacy Store located in the USA to CARE MART Inc. The Save Mart Pharmacy Store is owned by Natco Pharma Inc., a wholly owned subsidiary of the company, and is considered as a non-core part of the business.On 12 December 2016, Natco Pharma announced the launch of the first generic version of Oseltamivir oral capsules, 30 mg, 45 mg and 75 mg through its marketing partner Alvogen in the USA market. In 2017, Natco Pharma launched new cardiology and diabetology division for Indian market. On 2 January 2017, Natco Pharma announced that it has launched the first generic version of Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination in Nepal. Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination is sold by Gilead Sciences, Inc., under brand name Epclusa. Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for Ribavirin.On 17 May 2017, Natco Pharma announced that its partner Dr. Reddy's Laboratories Ltd. has received approval from the U.S. Food and Drug Administration (USFDA) to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil (doxorubicin hydrochloride liposome injection), for intravenous use, in the United States market.On 5 October 2017, Natco Pharma announced that its marketing partner Mylan N.V., has launched in the U.S. the first Glatiramer Acetate Injection 40 mg/mL for 3-times-a-week injection that is an AP-rated substitutable generic version of Teva's Copaxone 40 mg/mL, as well as Glatiramer Acetate Injection 20 mg/mL for once-daily injection, an AP-rated, substitutable generic version of Teva's Copaxone 20 mg/mL. These products are indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system. Shipments to customers have commenced.On 4 November 2017, Natco Pharma announced that it has executed definitive agreement and subscribed to 7.50% of the paid-up equity share capital of OMRV Hospitals Private Limited (OMRV). The investment amount was Rs 7.50 crore. OMRV operates under brand name of PACE Hospital which is a super specialty hospital presently operating in Hyderabad, Telangana focused on tertiary care services in the field of Medical and Surgical Gastroenterology, Hepatology, Nephrology, Urology, GI Oncology and Andrology.The Committee of Directors of Natco Pharma at its meeting held on 14 December 2017 approved allocation of 1 crore Equity Shares at the issue price of Rs 915 per Equity (including a premium of Rs. 913 per Equity Share) upon the closure of the issue, to eligible qualified institutional buyers pursuant to the QIP amounting to an Issue size of Rs 915 crore. On 17 February 2018, Natco Pharma completed regulatory inspection from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) facility in Mekaguda Village, near Hyderabad, India, which was conducted during the period 12th February, 2018 to 16th February, 2018, where the regulatory audit resulted in zero observations (no form 483 issued).During FY 2019-20, NATCO had 8 launches in the domestic market, 5 in cardiology and diabetology segment, and 3 in oncology segment. It launched a combination drug Vildanat M (Vildagliptin and Metformin) for diabetes, to achieve better blood glucose control and improve therapy compliance.During the period 2019-20, NATCO Life sciences Philippines Inc. was formed a fully owned subsidiary in the Philippines. During the year, it launched an FDC of Sofosbuvir-Daclatasvir tablets to treat Hepatitis C under the brand name 'Hepcinat Plus' and an oral fixed-dose combination of Sofosbuvir and Velapatasvir under their brand 'Velpanat'.The Company has 7 subsidiaries as on March 31, 2020. The Company has 7 international subsidiaries including 1 step-down subsidiary as on 31st March, 2021.In FY 2020-21, the Company launched generic Lenalidomide in South Africa.The Company has 8 international subsidiaries including 2 step-down subsidiaries as on 31st March, 2022.In FY 2021-22, Company through NATCO Pharma Inc., USA a wholly owned Subsidiary of Company acquired Dash Pharmaceuticals LLC, USA effective on 1st January, 2022, where Dash Pharmaceuticals LLC, USA is a step-down wholly owned Subsidiary Company of the Company. In Philippines, it launched first product, Liposomal Doxorubicin. In Australia, it received approval for Lenalidomide and Pomalidomide. It launched Sorafenib tablet in Taiwan with one year exclusivity. It launched first generic of Abiraterone tablets in Taiwan & Indonesia. It launched the Bendamustine Injection and Anastrozole tablets by the subsidiary named, Natco Lifesciences Philippines Inc. It launched the first generic of Oseltamivir in Brazil. It launched Everolimus in the US market. It launched 4 new products launched in 2021-22 such as Xpreza tablets, Pazonat, Cazanat and Tipanat for pateints suffering from liver, kidney and colorectal cancer. The Company launched the first generic version of Revlimid in the USA market in 2022. 11 new products launched in 2022-23. The Company launched Chlorantraniliprole (CTPR) pesticide formulation and its combinationproducts in liquid and granule forms. It launched a first generic alternative to the cancer drug Pomalidomide capsules sold underthe Pomalyst brand; launched Apixaban, Azacitidine in Philippines, Gefitinib, launched Oseltamivir capsules in the China market in 2023. It launched two Chlorantraniliprole (CTPR) pesticide formulation under brand names NATGEN and NATERRA and CTPR combination products under the brand names NATVOL and NATLIGO. It launched the first generic of Nat-Pomalidomide, Nat-Apixaban, and Nat-Teriflunomide in the market in the year 2023.The Company set up its subsidiaries in Indonesia, United Kingdom and Colombia to boost the global business in 2023-24. It enhanced the network coverage of Cardiology & Diabetology products in India in 2024.The Company launched new divisions such as `Dynami' for infectious diseases and `Hygeia' for Luminal Gastro and others. NATCO Pharma South Africa Proprietary Limited was incorporated as wholly owned subsidiary in South Africa in July, 2025.
Chairman / Executive Director / M D / Promoter
V C Nannapaneni
Registered office Natco House, Road No 2 Banjara Hills, Hyderabad, Telangana, 500033
FAX :91-040-23547532
Background
Incorporation Year 1981
Face Value ₹2.00
Market Lot 1
FAQs on Natco Pharma Ltd
How to buy Natco Pharma Ltd shares on NSE?
To buy Natco Pharma Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Natco Pharma Ltd share price today?
The Natco Pharma Ltd share price on NSE is ₹864.80 today.
What is the market cap of Natco Pharma Ltd on NSE?
The company has a market capitalization of ₹15489.42.
What is the PE & PB ratio of Natco Pharma Ltd?
PE is 10 and PB is 86.
What is the 52 Week High and Low of Natco Pharma Ltd shares?
Natco Pharma Ltd stock price high: ₹1505 Natco Pharma Ltd stock price low: ₹726.80.